+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antidote Market Size, Share & Trends Analysis Report by Type (Chemical Antidote, Physical Antidote, Pharmacological Antidote), Route Of Administration, Distribution Channel, End-use, Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 180 Pages
  • December 2023
  • Region: Global
  • Grand View Research
  • ID: 5921082
Description Jump to:
The global antidote market is expected to reach USD 3.58 billion by 2030, expanding at a CAGR of 7.60% from 2024 to 2030. The market is primarily driven by the incidence of snakebites and the adverse effects associated with them. For instance, according to a research article published on PLOS in 2023, approximately 58,000 deaths were recorded in India due to snake bites.

Moreover, surge in number of drug overdoses is driving the market. According to U.S. Department of Health & Human Services, about 106,699 drug overdose deaths were recorded in the U.S. in 2021. Antidote works to neutralize or reverse the toxic effects of specific drug. For instance, Naloxone is commonly used to reverse respiratory sedation and depression in opioid overdose rapidly. These capabilities of antidote are boosting the market growth.

Furthermore, rising prevalence of occupational poisoning is also contributing to the increased need for antidotes. Applications of antidote is rising owing to the growing incidence of opioid overdose, cyanide poisoning, carbon monoxide poisoning, lead poisoning, and organophosphate poisoning among others. For instance, as per NCBI research article, estimates in December 2020, approximately 385 million instances of unintentional pesticide poisoning occurred across the globe, including 11,000 deaths. Thus, the market is expected to grow rapidly during the forecast period.

Increasing R&D activities, launch, and approval of novel antidote drugs for treating several poisoning cases are anticipated to accelerate the growth during the projected period. For instance, in August 2023, Rising Pharmaceuticals, announced the launch and approval of Edetate calcium disodium injection for treating lead poisoning. In addition, in April 2021, Hikma Pharmaceuticals PLC, received U.S. approval of KLOXXADO TM nasal spray for treating opioid overdose. Such strategic initiatives by the key operating players are expected to boost the market.

Furthermore, a number of awareness activities to spread awareness regarding the identification of toxins aided with government initiatives to increase knowledge of antidotes and drugs is expected to drive the growth of overall market. However, limited availability of antidote due to manufacturing issues, regulatory obstacles, or economic factors can restrict access to life-saving antidotes. High costs of certain antidotes may pose financial barriers. In addition, storage requirements, shelf life limitations, and the need for specialized knowledge and training may restrict the applications of antidote. On the other hand, ongoing research and development efforts aim to improve availability, effectiveness, and safety in managing poisonings and toxic exposures are anticipated to offer lucrative opportunities for the market in the near future.

Antidote Market Report Highlights

  • By type, the chemical antidote dominated the antidote market in 2023 attributable to precise dosing, minimized compilations, and consistent outcomes
  • By route of administration, injectionheld the largest segment share of antidote market 2023, attributable to their rapid action and high specificity
  • By distribution channel, hospital pharmacies dominated the market in 2023. This growth can be attributed to numerous factors, including easy accessibility of antidote through hospital pharmacies
  • By end-use, the hospitals held the largest share in 2023. Increasing number of hospitalizations and treatments in the hospital settings is propelling overall growth
  • North America has established a strong regional position with a 33.57% share in 2023, owing to presence of key operating players, rising incidence of poisoning, and increasing research and development activities in the region

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Objectives
1.2.1. Objective - 1
1.2.2. Objective - 2
1.2.3. Objective - 3
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
3.5. Market Restraint Analysis
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Type Business Analysis
4.1. Antidote Market: Type Movement Analysis
4.2. Chemical Antidote
4.2.1. Chemical Antidote Market, 2018-2030 (USD Million)
4.3. Physical Antidote
4.3.1. Physical Antidote Market, 2018-2030 (USD Million)
4.4. Pharmacological Antidote
4.4.1. Pharmacological Antidote Market, 2018-2030 (USD Million)
Chapter 5. Route of Administration Business Analysis
5.1. Antidote Market: Route of Administration Movement Analysis
5.2. Oral
5.2.1. Oral Market, 2018-2030 (USD Million)
5.3. Topical
5.3.1. Topical Market, 2018-2030 (USD Million)
5.4. Injectable
5.4.1. Injectable Market, 2018-2030 (USD Million)
5.5. Others
5.5.1. Others Market, 2018-2030 (USD Million)
Chapter 6. Distribution Channel Business Analysis
6.1. Antidote Market: Distribution Channel Movement Analysis
6.2. Hospital Pharmacies
6.2.1. Hospital Pharmacies Market, 2018-2030 (USD Million)
6.3. Retail Pharmacies
6.3.1. Retail Pharmacies Market, 2018-2030 (USD Million)
6.4. Online Pharmacies
6.4.1. Cerebrospinal Fluid Market, 2018-2030 (USD Million)
Chapter 7. End Use Business Analysis
7.1. Antidote Market: Distribution Channel Movement Analysis
7.2. Hospitals
7.2.1. Hospitals Market, 2018-2030 (USD Million)
7.3. Homecare
7.3.1. Homecare Market, 2018-2030 (USD Million)
7.4. Specialty Clinics
7.4.1. Specialty Clinics Market, 2018-2030 (USD Million)
7.5. Others
7.5.1. Others Market, 2018-2030 (USD Million)
Chapter 8. Regional Business Analysis
8.1. Antidote Market Share By Region, 2023 & 2030
8.2. North America
8.2.1. North America Antidote market, 2018-2030 (USD Million)
8.2.2. U.S.
8.2.2.1. Key Country Dynamics
8.2.2.2. Target Disease Prevalence
8.2.2.3. Competitive Scenario
8.2.2.4. Regulatory Framework
8.2.2.5. Reimbursement Scenario
8.2.2.6. U.S. Antidote market, 2018-2030 (USD MILLION)
8.2.3. Canada
8.2.3.1. Key Country Dynamics
8.2.3.2. Target Disease Prevalence
8.2.3.3. Competitive Scenario
8.2.3.4. Regulatory Framework
8.2.3.5. Reimbursement Scenario
8.2.3.6. Canada Antidote market, 2018-2030 (USD Million)
8.3. Europe
8.3.1. Europe Antidote market, 2018-2030 (USD Million)
8.3.2. Germany
8.3.2.1. Key Country Dynamics
8.3.2.2. Target Disease Prevalence
8.3.2.3. Competitive Scenario
8.3.2.4. Regulatory Framework
8.3.2.5. Reimbursement Scenario
8.3.2.6. Germany Antidote market, 2018-2030 (USD Million)
8.3.3. UK
8.3.3.1. Key Country Dynamics
8.3.3.2. Target Disease Prevalence
8.3.3.3. Competitive Scenario
8.3.3.4. Regulatory Framework
8.3.3.5. Reimbursement Scenario
8.3.3.6. UK Antidote market, 2018-2030 (USD Million)
8.3.4. France
8.3.4.1. Key Country Dynamics
8.3.4.2. Target Disease Prevalence
8.3.4.3. Competitive Scenario
8.3.4.4. Regulatory Framework
8.3.4.5. Reimbursement Scenario
8.3.4.6. France Antidote market, 2018-2030 (USD Million)
8.3.5. Italy
8.3.5.1. Key Country Dynamics
8.3.5.2. Target Disease Prevalence
8.3.5.3. Competitive Scenario
8.3.5.4. Regulatory Framework
8.3.5.5. Reimbursement Scenario
8.3.5.6. Italy Antidote market, 2018-2030 (USD Million)
8.3.6. Spain
8.3.6.1. Key Country Dynamics
8.3.6.2. Target Disease Prevalence
8.3.6.3. Competitive Scenario
8.3.6.4. Regulatory Framework
8.3.6.5. Reimbursement Scenario
8.3.6.6. Spain Antidote market, 2018-2030 (USD Million)
8.3.7. Denmark
8.3.7.1. Key Country Dynamics
8.3.7.2. Target Disease Prevalence
8.3.7.3. Competitive Scenario
8.3.7.4. Regulatory Framework
8.3.7.5. Reimbursement Scenario
8.3.7.6. Denmark Antidote market, 2018-2030 (USD Million)
8.3.8. Sweden
8.3.8.1. Key Country Dynamics
8.3.8.2. Target Disease Prevalence
8.3.8.3. Competitive Scenario
8.3.8.4. Regulatory Framework
8.3.8.5. Reimbursement Scenario
8.3.8.6. Sweden Antidote market, 2018-2030 (USD Million)
8.3.9. Norway
8.3.9.1. Key Country Dynamics
8.3.9.2. Target Disease Prevalence
8.3.9.3. Competitive Scenario
8.3.9.4. Regulatory Framework
8.3.9.5. Reimbursement Scenario
8.3.9.6. Norway Antidote market, 2018-2030 (USD Million)
8.4. Asia-Pacific
8.4.1. Asia-Pacific Antidote market, 2018-2030 (USD Million)
8.4.2. Japan
8.4.2.1. Key Country Dynamics
8.4.2.2. Target Disease Prevalence
8.4.2.3. Competitive Scenario
8.4.2.4. Regulatory Framework
8.4.2.5. Reimbursement Scenario
8.4.2.6. Japan Antidote market, 2018-2030 (USD Million)
8.4.3. China
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Competitive Scenario
8.4.3.4. Regulatory Framework
8.4.3.5. Reimbursement Scenario
8.4.3.6. China Antidote market, 2018-2030 (USD Million)
8.4.4. India
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Competitive Scenario
8.4.4.4. Regulatory Framework
8.4.4.5. Reimbursement Scenario
8.4.4.6. India Antidote market, 2018-2030 (USD Million)
8.4.5. South Korea
8.4.5.1. Key Country Dynamics
8.4.5.2. Target Disease Prevalence
8.4.5.3. Competitive Scenario
8.4.5.4. Regulatory Framework
8.4.5.5. Reimbursement Scenario
8.4.5.6. South Korea Antidote market, 2018-2030 (USD Million)
8.4.6. Australia
8.4.6.1. Key Country Dynamics
8.4.6.2. Target Disease Prevalence
8.4.6.3. Competitive Scenario
8.4.6.4. Regulatory Framework
8.4.6.5. Reimbursement Scenario
8.4.6.6. Australia Antidote market, 2018-2030 (USD Million)
8.4.7. Thailand
8.4.7.1. Key Country Dynamics
8.4.7.2. Target Disease Prevalence
8.4.7.3. Competitive Scenario
8.4.7.4. Regulatory Framework
8.4.7.5. Reimbursement Scenario
8.4.7.6. Thailand Antidote market, 2018-2030 (USD Million)
8.5. Latin America
8.5.1. Latin America Antidote market, 2018-2030 (USD Million)
8.5.2. Brazil
8.5.2.1. Key Country Dynamics
8.5.2.2. Target Disease Prevalence
8.5.2.3. Competitive Scenario
8.5.2.4. Regulatory Framework
8.5.2.5. Reimbursement Scenario
8.5.2.6. Brazil Antidote market, 2018-2030 (USD Million)
8.5.3. Mexico
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Competitive Scenario
8.5.3.4. Regulatory Framework
8.5.3.5. Reimbursement Scenario
8.5.3.6. Mexico Antidote market, 2018-2030 (USD Million)
8.5.4. Argentina
8.5.4.1. Key Country Dynamics
8.5.4.2. Target Disease Prevalence
8.5.4.3. Competitive Scenario
8.5.4.4. Regulatory Framework
8.5.4.5. Reimbursement Scenario
8.5.4.6. Argentina Antidote market, 2018-2030 (USD Million)
8.6. MEA
8.6.1. MEA Antidote market, 2018-2030 (USD Million)
8.6.2. South Africa
8.6.2.1. Key Country Dynamics
8.6.2.2. Target Disease Prevalence
8.6.2.3. Competitive Scenario
8.6.2.4. Regulatory Framework
8.6.2.5. Reimbursement Scenario
8.6.2.6. South Africa Antidote market, 2018-2030 (USD Million)
8.6.3. Saudi Arabia
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Competitive Scenario
8.6.3.4. Regulatory Framework
8.6.3.5. Reimbursement Scenario
8.6.3.6. Saudi Arabia Antidote market, 2018-2030 (USD Million)
8.6.4. UAE
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Competitive Scenario
8.6.4.4. Regulatory Framework
8.6.4.5. Reimbursement Scenario
8.6.4.6. UAE Antidote market, 2018-2030 (USD Million)
8.6.5. Kuwait
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Competitive Scenario
8.6.5.4. Regulatory Framework
8.6.5.5. Reimbursement Scenario
8.6.5.6. Kuwait Antidote market, 2018-2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant’s overview
9.2. Financial performance
9.3. Participant categorization
9.3.1. Market Leaders
9.3.2. Antidote market Share Analysis, 2023
9.3.3. Company Profiles
9.3.3.1. Pfizer Inc
9.3.3.1.1. Company Overview
9.3.3.1.2. Financial Performance
9.3.3.1.3. Product Benchmarking
9.3.3.1.4. Strategic Initiatives
9.3.3.2. Hikma Pharmaceuticals PLC
9.3.3.2.1. Company Overview
9.3.3.2.2. Financial Performance
9.3.3.2.3. Product Benchmarking
9.3.3.2.4. Strategic Initiatives
9.3.3.3. Dr. Reddy’s Laboratories Ltd
9.3.3.3.1. Company Overview
9.3.3.3.2. Financial Performance
9.3.3.3.3. Product Benchmarking
9.3.3.3.4. Strategic Initiatives
9.3.3.4. Mylan N.V.
9.3.3.4.1. Company Overview
9.3.3.4.2. Financial Performance
9.3.3.4.3. Product Benchmarking
9.3.3.4.4. Strategic Initiatives
9.3.3.5. Fresenius Kabi AG
9.3.3.5.1. Company Overview
9.3.3.5.2. Financial Performance
9.3.3.5.3. Product Benchmarking
9.3.3.5.4. Strategic Initiatives
9.3.3.6. Zydus Lifesciences Ltd
9.3.3.6.1. Company Overview
9.3.3.6.2. Financial Performance
9.3.3.6.3. Product Benchmarking
9.3.3.6.4. Strategic Initiatives
9.3.3.7. Endo International plc
9.3.3.7.1. Company Overview
9.3.3.7.2. Financial Performance
9.3.3.7.3. Product Benchmarking
9.3.3.7.4. Strategic Initiatives
9.3.3.8. Novartis AG
9.3.3.8.1. Company Overview
9.3.3.8.2. Financial Performance
9.3.3.8.3. Product Benchmarking
9.3.3.8.4. Strategic Initiatives
9.3.3.9. Baxter International, Inc.
9.3.3.9.1. Company Overview
9.3.3.9.2. Financial Performance
9.3.3.9.3. Product Benchmarking
9.3.3.9.4. Strategic Initiatives
9.3.3.10. EMERGENT
9.3.3.10.1. Company Overview
9.3.3.10.2. Financial Performance
9.3.3.10.3. Product Benchmarking
9.3.3.10.4. Strategic Initiatives
9.3.4. Strategy Mapping
9.3.4.1. Expansion
9.3.4.2. Acquisition
9.3.4.3. Collaborations
9.3.4.4. Disease Type/Drug Class Launch
9.3.4.5. Partnerships
9.3.4.6. Others
List of Tables
Table 1 List of Abbreviations
Table 2 Global Antidote Market, by Type, 2018-2030 (USD Million)
Table 3 Global Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 4 Global Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 5 Global Antidote Market, by End Use, 2018-2030 (USD Million)
Table 6 Global Antidote Market, by Region, 2018-2030 (USD Million)
Table 7 North America Antidote Market, by Country, 2018-2030 (USD Million)
Table 8 North America Antidote Market, by Type, 2018-2030 (USD Million)
Table 9 North America Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 10 North America Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 11 North America Antidote Market, by End Use, 2018-2030 (USD Million)
Table 12 U.S. Antidote Market, by Type, 2018-2030 (USD Million)
Table 13 U.S. Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 14 U.S. Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 15 U.S. Antidote Market, by End Use, 2018-2030 (USD Million)
Table 16 Canada Antidote Market, by Type, 2018-2030 (USD Million)
Table 17 Canada Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 18 Canada Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 19 Canada Antidote Market, by End Use, 2018-2030 (USD Million)
Table 20 Europe Antidote Market, by Country, 2018-2030 (USD Million)
Table 21 Europe Antidote Market, by Type, 2018-2030 (USD Million)
Table 22 Europe Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 23 Europe Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 24 Europe Antidote Market, by End Use, 2018-2030 (USD Million)
Table 25 Germany Antidote Market, by Type, 2018-2030 (USD Million)
Table 26 Germany Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 27 Germany Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 28 Germany Antidote Market, by End Use, 2018-2030 (USD Million)
Table 29 UK Antidote Market, by Type, 2018-2030 (USD Million)
Table 30 UK Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 31 UK Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 32 UK Antidote Market, by End Use, 2018-2030 (USD Million)
Table 33 France Antidote Market, by Type, 2018-2030 (USD Million)
Table 34 France Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 35 France Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 36 France Antidote Market, by End Use, 2018-2030 (USD Million)
Table 37 Italy Antidote Market, by Type, 2018-2030 (USD Million)
Table 38 Italy Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 39 Italy Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 40 Italy Antidote Market, by End Use, 2018-2030 (USD Million)
Table 41 Spain Antidote Market, by Type, 2018-2030 (USD Million)
Table 42 Spain Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 43 Spain Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 44 Spain Antidote Market, by End Use, 2018-2030 (USD Million)
Table 45 Denmark Antidote Market, by Type, 2018-2030 (USD Million)
Table 46 Denmark Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 47 Denmark Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 48 Denmark Antidote Market, by End Use, 2018-2030 (USD Million)
Table 49 Sweden Antidote Market, by Type, 2018-2030 (USD Million)
Table 50 Sweden Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 51 Sweden Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 52 Sweden Antidote Market, by End Use, 2018-2030 (USD Million)
Table 53 Norway Antidote Market, by Type, 2018-2030 (USD Million)
Table 54 Norway Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 55 Norway Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 56 Norway Antidote Market, by End Use, 2018-2030 (USD Million)
Table 57 Asia-Pacific Antidote Market, by Country, 2018-2030 (USD Million)
Table 58 Asia-Pacific Antidote Market, by Type, 2018-2030 (USD Million)
Table 59 Asia-Pacific Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 60 Asia-Pacific Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 61 Asia-Pacific Antidote Market, by End-use, 2018-2030 (USD Million)
Table 62 China Antidote Market, by Type, 2018-2030 (USD Million)
Table 63 China Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 64 China Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 65 China Antidote Market, by End Use, 2018-2030 (USD Million)
Table 66 Japan Antidote Market, by Type, 2018-2030 (USD Million)
Table 67 Japan Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 68 Japan Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 69 Japan Antidote Market, by End Use, 2018-2030 (USD Million)
Table 70 India Antidote Market, by Type, 2018-2030 (USD Million)
Table 71 India Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 72 India Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 73 India Antidote Market, by End Use, 2018-2030 (USD Million)
Table 74 South Korea Antidote Market, by Type, 2018-2030 (USD Million)
Table 75 South Korea Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 76 South Korea Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 77 South Korea Antidote Market, by End Use, 2018-2030 (USD Million)
Table 78 Australia Antidote Market, by Type, 2018-2030 (USD Million)
Table 79 Australia Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 80 Australia Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 81 Australia Antidote Market, by End Use, 2018-2030 (USD Million)
Table 82 Thailand Antidote Market, by Type, 2018-2030 (USD Million)
Table 83 Thailand Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 84 Thailand Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 85 Thailand Antidote Market, by End Use, 2018-2030 (USD Million)
Table 86 Latin America Antidote Market, by Country, 2018-2030 (USD Million)
Table 87 Latin America Antidote Market, by Type, 2018-2030 (USD Million)
Table 88 Latin America Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 89 Latin America Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 90 Latin America Antidote Market, by End Use, 2018-2030 (USD Million)
Table 91 Brazil Antidote Market, by Type, 2018-2030 (USD Million)
Table 92 Brazil Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 93 Brazil Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 94 Brazil Antidote Market, by End Use, 2018-2030 (USD Million)
Table 95 Mexico Antidote Market, by Type, 2018-2030 (USD Million)
Table 96 Mexico Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 97 Mexico Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 98 Mexico Antidote Market, by End Use, 2018-2030 (USD Million)
Table 99 Argentina Antidote Market, by Type, 2018-2030 (USD Million)
Table 100 Argentina Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 101 Argentina Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 102 Argentina Antidote Market, by End Use, 2018-2030 (USD Million)
Table 103 Middle East & Africa Antidote Market, by Type, 2018-2030 (USD Million)
Table 104 Middle East & Africa Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 105 Middle East & Africa Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 106 Middle East & Africa Antidote Market, by Type, 2018-2030 (USD Million)
Table 107 Middle East & Africa Antidote Market, by End Use, 2018-2030 (USD Million)
Table 108 South Africa Antidote Market, by Type, 2018-2030 (USD Million)
Table 109 South Africa Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 110 South Africa Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 111 South Africa Antidote Market, by End Use, 2018-2030 (USD Million)
Table 112 Saudi Arabia Antidote Market, by Type, 2018-2030 (USD Million)
Table 113 Saudi Arabia Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 114 Saudi Arabia Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 115 Saudi Arabia Antidote Market, by End Use, 2018-2030 (USD Million)
Table 116 UAE Antidote Market, by Type, 2018-2030 (USD Million)
Table 117 UAE Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 118 UAE Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 119 UAE Antidote Market, by End Use, 2018-2030 (USD Million)
Table 120 Kuwait Antidote Market, by Type, 2018-2030 (USD Million)
Table 121 Kuwait Antidote Market, by Route of Administration, 2018-2030 (USD Million)
Table 122 Kuwait Antidote Market, by Distribution Channel, 2018-2030 (USD Million)
Table 123 Kuwait Antidote Market, by End Use, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Information Procurement
Figure 3 Primary Research Pattern
Figure 4 Market Research Approaches
Figure 5 Value Chain-Based Sizing & Forecasting
Figure 6 Market Formulation & Validation
Figure 7 Antidote Market Segmentation
Figure 8 Market Snapshot, 2023
Figure 9 Market Trends & Outlook
Figure 10 Market Driver Relevance Analysis (Current & Future Impact)
Figure 11 Market Restraint Relevance Analysis (Current & Future Impact)
Figure 12 PESTEL Analysis, By Factor (Political & Legal, Economic and Technological)
Figure 13 Porter’s Five Forces Analysis
Figure 14 Global Antidote Market: Type Movement Analysis
Figure 15 Global Antidote Market, by Chemical Antidote, 2018-2030 (USD Million)
Figure 16 Global Antidote Market, by Physical Antidote, 2018-2030 (USD Million)
Figure 17 Global Antidote Market, by Pharmacological Antidote, 2018-2030 (USD Million)
Figure 18 Global Antidote Market: Route of Administration Movement Analysis
Figure 19 Global Antidote Market, by Oral, 2018-2030 (USD Million)
Figure 20 Global Antidote Market, by Topical, 2018-2030 (USD Million)
Figure 21 Global Antidote Market, by Injectable, 2018-2030 (USD Million)
Figure 22 Global Antidote Market, by Others, 2018-2030 (USD Million)
Figure 23 Global Antidote Market: Distribution Channel Movement Analysis
Figure 24 Global Antidote Market, by Hospital Pharmacies 2018-2030 (USD Million)
Figure 25 Global Antidote Market, by Retail Pharmacies 2018-2030 (USD Million)
Figure 26 Global Antidote Market, by Online Pharmacies, 2018-2030 (USD Million)
Figure 27 Global Antidote Market: End Use Movement Analysis
Figure 28 Global Antidote Market, by Hospitals 2018-2030 (USD Million)
Figure 29 Global Antidote Market, by Homecare 2018-2030 (USD Million)
Figure 30 Global Antidote Market, by Speciality Clinics, 2018-2030 (USD Million)
Figure 31 Global Antidote Market, by Others, 2018-2030 (USD Million)
Figure 32 Regional Marketplace: Key Takeaways
Figure 33 Regional Outlook, 2023 & 2030
Figure 34 Global Antidote Market: Region Movement Analysis
Figure 35 North America Antidote Market, 2018-2030 (USD Million)
Figure 36 U.S. Antidote Market, 2018-2030 (USD Million)
Figure 37 Canada Antidote Market, 2018-2030 (USD Million)
Figure 38 Europe Antidote Market, 2018-2030 (USD Million)
Figure 39 Germany Antidote Market, 2018-2030 (USD Million)
Figure 40 UK Antidote Market, 2018-2030 (USD Million)
Figure 41 France Antidote Market, 2018-2030 (USD Million)
Figure 42 Italy Antidote Market, 2018-2030 (USD Million)
Figure 43 Spain Antidote Market, 2018-2030 (USD Million)
Figure 44 Denmark Antidote Market, 2018-2030 (USD Million)
Figure 45 Sweden Antidote Market, 2018-2030 (USD Million)
Figure 46 Norway Antidote Market, 2018-2030 (USD Million)
Figure 47 Asia-Pacific Antidote Market, 2018-2030 (USD Million)
Figure 48 Japan Antidote Market, 2018-2030 (USD Million)
Figure 49 China Antidote Market, 2018-2030 (USD Million)
Figure 50 India Antidote Market, 2018-2030 (USD Million)
Figure 51 Australia Antidote Market, 2018-2030 (USD Million)
Figure 52 South Korea Antidote Market, 2018-2030 (USD Million)
Figure 53 Thailand Antidote Market, 2018-2030 (USD Million)
Figure 54 Latin America Antidote Market, 2018-2030 (USD Million)
Figure 55 Brazil Antidote Market, 2018-2030 (USD Million)
Figure 56 Mexico Antidote Market, 2018-2030 (USD Million)
Figure 57 Argentina Antidote Market, 2018-2030 (USD Million)
Figure 58 Middle East and Africa Antidote Market, 2018-2030 (USD Million)
Figure 59 South Africa Antidote Market, 2018-2030 (USD Million)
Figure 60 Saudi Arabia Antidote Market, 2018-2030 (USD Million)
Figure 61 UAE Antidote Market, 2018-2030 (USD Million)
Figure 62 Kuwait Antidote Market, 2018-2030 (USD Million)

Companies Mentioned

  • Pfizer Inc
  • Hikma Pharmaceuticals PLC
  • Dr. Reddy’s Laboratories Ltd
  • Mylan N.V.
  • Fresenius Kabi AG
  • Zydus Lifesciences Ltd
  • Endo International plc
  • Novartis AG
  • Baxter International, Inc.
  • EMERGENT

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages180
PublishedDecember 2023
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 2.16 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.58 Billion
Compound Annual Growth Rate7.6%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Antidote Market Analysis & Forecast to 2024-2034 - Product Image

Antidote Market Analysis & Forecast to 2024-2034

  • Report
  • 200 Pages
  • Global
From
Antidotes Global Market Report 2024 - Product Image

Antidotes Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Antidotes to Toxins and Drugs. From Natural Sources to Drug Discovery in Toxicology. Drug Discovery Update - Product Image

Antidotes to Toxins and Drugs. From Natural Sources to Drug Discovery in Toxicology. Drug Discovery Update

  • Book
Sulphonamides Market by Form, Route of Administration, Distribution Channel, Application - Global Forecast 2025-2030 - Product Image

Sulphonamides Market by Form, Route of Administration, Distribution Channel, Application - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Anti-vascular Endothelial Growth Factor Therapeutics Market by Therapeutic Type, Route of Administration, Indication - Global Forecast 2025-2030 - Product Image

Anti-vascular Endothelial Growth Factor Therapeutics Market by Therapeutic Type, Route of Administration, Indication - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From

About the Antidotes Market

The Antidotes market is a subset of the Drugs by Therapeutic Area market, focusing on drugs used to counteract the effects of a poison or toxin. Antidotes are used to treat a wide range of conditions, from acute poisoning to chronic illnesses. They can be administered orally, intravenously, or topically, depending on the type of poison or toxin. Antidotes can be used to treat both acute and chronic conditions, and can be used in combination with other treatments. The Antidotes market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and Novartis. Other companies in the market include AstraZeneca, Bristol-Myers Squibb, and Eli Lilly. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.